{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:38:30Z","timestamp":1793194710220,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001732","name":"Danmarks Grundforskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.biopha.2023.114969","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:43:25Z","timestamp":1685580205000},"page":"114969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss"],"prefix":"10.1016","volume":"164","author":[{"given":"Anna Thors\u00f8","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone A.","family":"Melander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Sonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Bredtoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mays","family":"Al-Rubai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten A.","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.114969_bib1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-Week, open-Label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2023.114969_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2023.114969_bib3","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1152\/ajpendo.00121.2014","article-title":"A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats","volume":"307","author":"Andreassen","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2023.114969_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101282","article-title":"KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats","volume":"53","author":"Andreassen","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2023.114969_bib5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, mul","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2023.114969_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1\u20137 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.biopha.2023.114969_bib7","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(21)00944-2","article-title":"Cagrilintide plus semaglutide for obesity management","volume":"397","author":"Becerril","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114969_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2023.114969_bib9","first-page":"1032","article-title":"Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man","volume":"74","author":"Bretherton-Watt","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2023.114969_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2023.114969_bib11","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"10.1016\/j.biopha.2023.114969_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2021.807548","article-title":"Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales","volume":"12","author":"Dahl\u00e9n","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114969_bib13","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114969_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114969_bib15","unstructured":"FDA (U.S. Food and Drug Administration) (2021). FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014."},{"key":"10.1016\/j.biopha.2023.114969_bib16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2023.114969_bib17","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/S0140-6736(21)01999-1","article-title":"Long-acting amylin analogue for weight reduction","volume":"398","author":"Gadde","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114969_bib18","first-page":"2","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","author":"Garvey","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2023.114969_bib19","first-page":"2015","article-title":"KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight","volume":"00514","author":"Gydesen","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab. Ajpendo"},{"key":"10.1016\/j.biopha.2023.114969_bib20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114969_bib21","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2023.114969_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejphar.2015.05.051","article-title":"KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration","volume":"762","author":"Hjuler","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114969_bib23","article-title":"The dual amylin- and calcitonin receptor agonist KBP-042 works as adjunct to metformin on fasting hyperglycaemia and HbA1c in a rat model of type 2 diabetes","volume":"117","author":"Hjuler","year":"2017","journal-title":"J. Pharmacol. Exp. Ther. jpet."},{"key":"10.1016\/j.biopha.2023.114969_bib24","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/oby.21563","article-title":"The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity","volume":"24","author":"Hjuler","year":"2016","journal-title":"Obesity"},{"key":"10.1016\/j.biopha.2023.114969_bib25","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2023.114969_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2021.113435","article-title":"Hypoglycemia attenuates acute amylin-induced reduction of food intake in male rats","volume":"237","author":"Honegger","year":"2021","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.biopha.2023.114969_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1124\/jpet.119.263400","article-title":"Dose frequency optimization of the dual amylin and calcitonin receptor agonist KBP-088 \u2013 long-lasting improvement of food preference and body weight loss","volume":"373","author":"Larsen","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2023.114969_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/jpet.119.263392","article-title":"The calcitonin receptor plays a major role in glucose regulation as a function of dual amylin and calcitonin receptor agonist therapy","volume":"374","author":"Larsen","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2023.114969_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-020-00678-2","article-title":"The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile","volume":"21","author":"Larsen","year":"2021","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.biopha.2023.114969_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1124\/jpet.119.257576","article-title":"The dual amylin and calcitonin receptor agonist KBP-088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy","volume":"370","author":"Larsen","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2023.114969_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biopha.2022.113842","article-title":"Does receptor balance matter\u00a0? \u2013 Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models","volume":"156","author":"Larsen","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2023.114969_bib32","first-page":"6736","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, dose-finding phase 2 trial","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114969_bib33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114969_bib34","unstructured":"Novo Nordisk A\/S (2022). Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes."},{"key":"10.1016\/j.biopha.2023.114969_bib35","first-page":"1083","article-title":"Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin- dependent diabetes mellitus","volume":"81","author":"Nyholm","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2023.114969_bib36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng0596-18","article-title":"Leptin receptor missense mutation in the fatty Zucker rat","volume":"13","author":"Phillips","year":"1996","journal-title":"Nat. Genet"},{"key":"10.1016\/j.biopha.2023.114969_bib37","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet. Med."},{"key":"10.1016\/j.biopha.2023.114969_bib38","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.2337\/dc07-0589","article-title":"Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin","volume":"30","author":"Riddle","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2023.114969_bib39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114969_bib40","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.biopha.2023.114969_bib41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/DDDT.S3225","article-title":"Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes","volume":"2","author":"Ryan","year":"2008","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.biopha.2023.114969_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines10102365","article-title":"The impact of exposure profile on the efficacy of dual amylin and calcitonin receptor agonist therapy","volume":"10","author":"Sonne","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2023.114969_bib43","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2023.114969_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1152\/ajplegacy.1956.187.1.15","article-title":"Measurement of size and turnover rate of body glucose pool by the isotope dilution method","volume":"187","author":"Steele","year":"1956","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.biopha.2023.114969_bib45","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1210\/en.2010-0590","article-title":"Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats","volume":"151","author":"Trevaskis","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2023.114969_bib46","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2023.114969_bib47","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control","volume":"7","author":"Weyer","year":"2001","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2023.114969_bib48","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"Cmaj"},{"key":"10.1016\/j.biopha.2023.114969_bib49","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s001250050088","article-title":"Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans","volume":"37","author":"Wilding","year":"1994","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2023.114969_bib50","first-page":"2014","article-title":"The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp","author":"Wu","year":"2014","journal-title":"J. Diabetes Res"},{"key":"10.1016\/j.biopha.2023.114969_bib51","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1210\/en.2013-2157","article-title":"Liraglutide enhances insulin sensitivity by activating amp-activated protein kinase in male wistar rats","volume":"155","author":"Yamazaki","year":"2014","journal-title":"Endocrinology"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222300759X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222300759X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:19:27Z","timestamp":1793193567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222300759X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":51,"alternative-id":["S075333222300759X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114969","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114969"}}